高血壓 (ARB) 高血壓 (CCB) Management of hypertension (monotherapy or with other antihypertensive agents).

Amlodipine: Directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure. Olmesartan: Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II.(UTD)

See individual agents.

Concomitant use with aliskiren in patients with diabetes mellitus Documentation of allergenic cross-reactivity for angiotensin receptor blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected. See individual agents.(UTD)

Amlodipine is excreted in breast milk ; excretion of olmesartan is unknown. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.

>10%: Cardiovascular: Peripheral edema (dose related: 18% to 26%).

Dosage is individualized. Initial: Amlodipine 5 mg/olmesartan 20 mg once daily; dose may be increased after 1 to 2 weeks of therapy. Maximum dose: Amlodipine 10 mg/olmesartan 40 mg per day.

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).(UTD)

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).(UTD)